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Abstract
Background: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Based on
previous promising experiences within a clinical trial involving carboplatin and paclitaxel a series of advanced metastatic
melanoma patients were treated with this combination.
Methods: Data of all patients with cutaneous metastatic melanoma treated with carboplatin and paclitaxel (CP) at our
institution between October 2005 and December 2007 were retrospectively evaluated. For all patients a once-every-3-weeks
dose-intensified regimen was used. Overall and progression free survival were calculated using the method of Kaplan and
Meier. Tumour response was evaluated according to RECIST criteria.
Results: 61 patients with cutaneous metastatic melanoma were treated with CP. 20 patients (85% M1c) received CP as first-
line treatment, 41 patients (90.2% M1c) had received at least one prior systemic therapy for metastatic disease. Main
toxicities were myelosuppression, fatigue and peripheral neuropathy. Partial responses were noted in 4.9% of patients,
stable disease in 23% of patients. No complete response was observed. Median progression free survival was 10 weeks.
Median overall survival was 31 weeks. Response, progression-free and overall survival were equivalent in first- and second-
line patients. 60 patients of 61 died after a median follow up of 7 months. Median overall survival differed for patients with
controlled disease (PR+SD) (49 weeks) compared to patients with progressive disease (18 weeks).
Conclusions: Among patients with metastatic melanoma a subgroup achieved disease control under CP therapy which may
be associated with a survival benefit. This potential advantage has to be weighed against considerable toxicity. Since
response rates and survival were not improved in previously untreated patients compared to pretreated patients, CP should
thus not be applied as first-line treatment.
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Introduction
Melanoma is an increasingly common disease, and its incidence
still rises in the industrialized countries with white populations.
Although primary cutaneous melanomas are frequently curable by
surgical excision, metastatic melanoma carries a poor prognosis
with a median survival ranging from 6 to 12 months, and has not
improved during the last three decades. In the US 8700 patients
are expected to die of metastatic melanoma in the year 2010 [1].
Metastatic melanoma is a solid tumour that is relatively resistant
to systemic treatment [2]. However, chemotherapy with one or
more drugs can produce palliative clinical responses in some
patients [3]. Currently only dacarbazine and interleukin-2 have
been approved for routine therapy of metastatic melanoma. As the
majority of patients progress under this treatment or have only
short time responses, there is a strong need for second-line
treatment options.
Combined chemotherapy with carboplatin and paclitaxel (CP) is a
well established treatment regimen in advanced non-small-cell lung
cancer and in advanced ovarian cancer [4–8]. Carboplatin replaced
cisplatin from previous combined regimens demonstrating equal
efficacy and less toxicity [9]. This regimen has been used in order to
examine combined effects with sorafenib in solid tumours, and,
interestingly, melanoma showed promising responses [10]. There-
fore,thecombinationwithsorafenibwasstudiedincomparisontoCP
alone in metastatic melanoma as second-line treatment. Surprisingly,
CP treatment results in a long median progression-free survival of
four months but sorafenib did not add additional efficacy. Based on
the promising results with CP treatment of metastatic melanoma in
this phase III trial, many centers introduced this chemotherapy
regimen in the treatment of disseminated melanoma, particularly in
the second line treatment situation [11]. We started to treat patients
with advanced metastatic melanoma with CP in October 2005.
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one or more prior systemic treatments or in case of primarily
rapidly progressive disease. The aim of this retrospective analysis
was to investigate the effectiveness of CP in advanced melanoma
patients in terms of overall survival and response and to compare
the results between first and second line treatment.
Methods
All patients with advanced metastastic melanoma of cutaneous
origin receiving CP at our institution between October 2005 and
December 2007 were included. Patients with melanoma of ocular
origin were excluded. Approval for this retrospective analysis was
obtained by the Ethics commitee Tuebingen, German (approval
number 384/2010A). Patient data of our own institution were
analyzed anonymously, therefore we did not obtain informed
consent. This approach was in accordance with the advice of our
ethics committee. Approval for this study was gained retrospec-
tively.
Based on the treatment schedule of the second-line CP plus
sorafenib trial all patients received intravenous paclitaxel 225 mg/
m
2 plus intravenous carboplatin at area under curve 6 (AUC 6) on
day 1 of a 21-day cycle, with a dose reduction after the fourth cycle
to carboplatin AUC 5 and paclitaxel 175/mg/m
2. Some patients
in poor general condition or insufficient myelofunction received a
reduced dose from the start of treatment. All patients who received
at least one cycle were included in the analysis.
Tumour evaluation was based on CT or PET-CT scans, which
were obtained after every 3
rd cycle (every 9 weeks). Tumour
response was evaluated using Response Evaluation Criteria in
Solid Tumours (RECIST) criteria [12]. Best response to treatment
was classified as complete response (CR) (no clinical or radiologic
evidence of disease), partial response (PR) (30% decrease in the
sum of the longest diameter), stable disease, and progression of
disease (20% increase in the sum of the longest diameter or new
lesion). All response evaluations were independently evaluated
by a second radiologist and demonstrated to the interdisciplinary
skin tumour board at the University Hospital of Tuebingen,
Germany.
Statistical analyses were performed with the statistical software
SPSS 15.0 (SPSS Inc., Chicago, Illinois, USA). In order to check
comparability, first-line and second-line group of patients were
compared for the characteristics gender, age, disease classification,
brain metastases, liver metastases, number of organs involved,
ECOG and LDH level prior to therapy. Bivariate statistical testing
was performed using two-sided Chi-square tests. P-values of less
than 0.05 were considered statistically significant. Follow up was
measured from start of treatment until death or last date of
observation. Progression-free survival (PFS) was defined from start
of treatment to first documented disease progression. Overall
survival (OS) was defined from the start of treatment to the date of
death. Non melanoma related deaths were included as censored
events. Survival probabilities were calculated according to Kaplan-
Meier and compared with log-rank test statistics [13].








N=41, n (%) p-value
Sex
male 34 (56%) 16 (80%) 18 (44%) 0.008
female 27 (44%) 4 (20%) 23 (56%)








IIIC 1 (2%) - 1 (2%) n.s.
M1b 6 (10%) 3 (15%) 3 (7%)
M1c 54 (89%) 17 (85%) 37 (90%)
Brain metastasis prior to therapy with CP 22 (36%) 10 (50%) 12 (29%) n.s.
LDH
upper normal limit 42 (69%) 15 (75%) 27 (66%) n.s.
normal limit 18 (30%) 5 (15%) 13 (32%)
No. of organs involved
1 organ 7 (12%) 1 (5%) 6 (15%) n.s.
2 organs 8 (13%) 1 (5%) 7 (17%)
3 organs 13 (21%) 4 (20%) 9 (22%)
4 or more organs 33 (54%) 14 (70%) 19 (46%)
ECOG prior therapy
0 21 (34%) 7 (35%) 14 (34%) n.s.
1 21 (34%) 5 (25%) 16 (39%)
2 15 (25%) 5 (25%) 10 (24%)
3 3 (5%) 3 (15%) -
4 1 (2%) - 1 (2%)
doi:10.1371/journal.pone.0016882.t001
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Patient characteristics
A total of 61 patients were identified for evaluation. Patient
characteristics are shown in Table 1. 20 patients (32.8%) received
CP as first-line therapy, 33 patients (54.1%) as second-line therapy,
eight patients (13.1%) had more than one previous therapy. The
median age at start of treatment was 53 years (range 20–79).
Concerning the M-classification 54 patients had M1c disease
(88.5%), six patients had M1b disease (9.8%), one patient had
unresectable stage IIIC disease (1.6%). 22 patients (36.1%) had
brain metastases or a history of brain metastases. Six of these 22
patients were treated by surgery, three by stereotactic radiation,
nine patients by whole brain radiotherapy and 4 patients had no
additional treatment for their brain metastases. 32 patients (52.5%)
had liver metastases. The median number of organ sites involved
was four (range 1–7). Only 21 patients (34.4%) had normal
Eastern Cooperative Oncology Group (ECOG) performance
status (PS) prior therapy.
Treatment and toxicity
The majority of patients (82%) received the full dosage at start
of CP treatment, 18% received the already reduced level
(carboplatin AUC 5 and paclitaxel 175/mg/m
2). The median
number of cycles of therapy delivered was four (range 1 to 20). 13
patients (21.3%) received only one cycle of therapy due to clinical
disease progression, intolerability or death.
Dose limiting toxicities (grade III and IV) were myelosuppres-
sion and peripheral neuropathy. Other frequent toxicities included
alopecia and fatigue. In four patients (6.6%) hypersensitivity
reactions to paclitaxel occurred. In all of this four patients a rapid
desensitization protocol according to a scheme proposed by Lee et
al was used to continue therapy [14].
Response to treatment
All 61 patients had measurable disease by RECIST criteria and
were assessable for response. Response rates are shown in Table 2.
Partialresponse wasnotedin4.9% ofpatients, stable disease in23%
of patients. No complete response was observed. Median progres-
sion free survival was 10 weeks (IQR = [7, 16]). Median overall
survival was 31 weeks (IQR = [14, 52]). Response rates as well as
progression and disease free survival were equivalent in first- and
second-line patients (Figure 1 and 2). Median duration of stability
was 22 weeks among the patients with stable disease (n=14).
There were no significant differences between patients receiving
CP as first-line therapy and second-line therapy regarding S100
levels, LDH levels, ECOG performance status, number of organs
Figure 1. Overall survival. Probability of overall survival after start of treatment in first-line and second-line patients. First-line patients: dotted line,
second-line patients: bold line. (p=0.961).
doi:10.1371/journal.pone.0016882.g001













CR ---n . s .
PR 3 (4.9%) 1 (5%) 2 (4.9%)
SD 14 (23%) 6 (30%) 8 (20%)
doi:10.1371/journal.pone.0016882.t002
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group of patients included significantly more male (p=0.008) and
young patients (p=0.011). Among the 22 patients with brain
metastases none showed an objective response upon treatment
with CP, however stabilisation of disease was observed in 5
patients. After a median follow up of 7 months 60 of 61 patients
had died. Median overall survival was 49 weeks (IQR = [31, 79])
for patients with controlled disease (partial response and stable
disease) compared to 18 weeks (IQR = [10. 35]) for patients with
progressive disease (p=0.001) (Figure 3).
There were no significant differences between patients with
controlled and progressive disease regarding number of organs
involved, presence of brain metastases, presence of liver metasta-
ses, age, gender and S100 levels. In contrast, a LDH value over
two-fold-upper normal limit at start of CP treatment was
significantly associated with progressive disease during therapy
(p=0.009). Decreasing or constant LDH levels under therapy
were associated with a prolonged overall survival (p=0.002).
Discussion
The present patient collective consisted of patients with clearly
progressive metastatic melanoma presenting with widespread
metastatic disease. Two third of patients had already received a
first-line chemotherapy mainly consisting in dacarbazine-based
treatments. First-line patients with extensive metastatic disease
were primarily treated with CP because the caring physicians felt
that they will be unlikely to respond to dacarbazine. Response to
CP treatment was low with five percent of partial responses as well
in first-line as in second-line treatment situations. However, 23%
of patients achieved stable disease which contributed obviously
similarly to prolongation of survival. Thus, temporary disease
control was attained in 28% of patients and seemed to be
associated with prolongation of survival to 49 weeks as compared
to 18 weeks in patients with progressive disease. The CP regimen
showed transient disease stabilisations but neither complete
responses nor long-term durable responses were accomplished.
In one patient the treatment with CP enabled a complete resection
of remaining metastases but the patient recurred afterwards. The
only patient alive achieved stable disease under CP treatment and
was included in a clinical trial with an anti-CTLA 4 antibody, then
achieved a CR and has no evidence of disease to date.
Toxicities were manageable in all cases but dose limiting
toxicities like myelosuppression and peripheral neuropathy
occurred as already described in other tumour entities [15–17].
Several studies investigated the combination of CP in metastatic
melanoma with different treatment schedules, results and conclu-
sions [11,18–21]. (Table 3) Only 19 patients of our study comply
with three main inclusion criteria (ECOG performance status 0 or
1, no cerebral metastases, not more than one prior therapy) of the
largest randomized trial by Hauschild et al. It is therefore not
possible to compare the two cohorts. The varying results may thus
be influenced by different patient selection criteria. The results of
our study regarding PFS and OS are similar to a retrospective study
published 2005 by Rao et al. [21] Likewise patient characteristics
are similar. Both studies reflect the real composition of advanced
metastatic melanoma patient cohort in clinical routine.
In the current study additionally first-line patients were
included. Survival curves for OS and PFS were remarkably
identical for the cohorts of patients receiving CP as first and
second-line treatment. It is noteworthy to mention that only
Figure 2. Progression free survival. Probability of progression free survival after start of treatment in first-line and second-line patients. First-line
patients: dotted line, second-line patients: bold line. (p=0.322).
doi:10.1371/journal.pone.0016882.g002
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have been included into this protocol.
The only observed significant difference between patients with
controlled and progressive disease was the level of LDH at
treatment start. LDH may therefore be considered as a predictive
factor for response. It seems to be more likely that factors like
tumour load (associated with LDH-level) and number of organs
involved but not the aggressiveness and sequence of the applied
chemotherapeutic schedules predict treatment responses.
CP therapy in metastatic melanoma has cytostatic effects with
achievement of disease control for limited time periods in about
one third of patients treated. Complete remissions or durable
responses have not been accomplished. It seems not to be a better
alternative to dacarbazine treatment in the first-line therapy, and
Figure 3. Overall survival in patients with disease control and progressive disease. Probability of overall survival after start of treatment in
patients with disease control (SD+PR) and in patients with progressive disease (PD). Patients with disease control: dotted line, patients with
progressive disease: bold line. (p=0.001).
doi:10.1371/journal.pone.0016882.g003
Table 3. Results of published studies on the combination of carboplatin and paclitaxel in patients with metastatic melanoma.
Current analysis Hausschild et al. Perez et al. Rao et al.
Zimpfer-
Rechner et al. Hodi et al.












weekly every 3 wk
No of patients 61 135 53 31 19 15
Median age y 53 56 55 59.6 57.6 54
Prior chemotherapy (% of pat.) 67.2 100 24.5 100 100 no data
M1c (% of pat.) 88.5 69 79 84 no data 39
CR (% of pat.) 000000
PR (% of pat.) 4.9 11 17 26 0 26
SD (% of pat.) 23 51 57 19 16 47
Median PFS (wk) 10 17.9 26 12 8 no data
Median OS (wk) 31 42 52 31 30 36
doi:10.1371/journal.pone.0016882.t003
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response to therapy may be associated with a prolonged overall
survival. The indication for CP therapy has to be considered on an
individual basis and has to be weighed against considerable
toxicity.
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